Abstract Objective To study the clinical characteristics of ecotopic viral integration site-1 (EVI1) and BCR/ABL positive childhood leukemia. Methods Clinical data of four children with EVI1 and BCR/ABL positive leukemia and eight children with BCR/ABL positive but EVI1 negative chronic myeloid leukemia (CML) were retrospectively analyzed. Results In the four children with EVI1 and BCR/ABL positive leukemia, two were initially diagnosed with chronic phase of CML, one with accelerated phase of CML and one with high-risk acute lymphoblastic leukemia (ALL). There were no significant differences in clinical characteristics at diagnosis between the patients with EVI1 and BCR/ABL positive leukemia and BCR/ABL positive but EVI1 negative leukemia. CD33 and CD38 were highly expressed and t(9;22) abnormality was present in all patients with EVI1 and BCR/ABL positive leukemia. Two of the 3 children with EVI1 and BCR/ABL positive CML achieved complete remission one or three months after treatment. Acquired negative status conversion occurred for EVI1 but not BCR/ABL in one CML case. The 3 children with EVI1 and BCR/ABL positive CML survived 20, 13 and 14 months, respectively, without recurrence. The child with EVI1 and BCR/ABL positive ALL failed to achieve complete remission after the first course of treatment and discontinued further treatment. Conclusions Co-expression of EVI1 and BCR/ABL fusion gene can be found in childhood CML and ALL. The relatively rare leukemia has not significant difference respect to clinical characteristics. Prognosis of the disease needs to be determined by clinical studies with a larger sample size.
Toydemir R, Rowe L, Hibbard M, et al. Cytogenetic and molecular characterization of double inversion 3 associated with a cryptic BCR-ABL1 rearrangement and additional genetic changes[J]. Cancer Genet Cytogenet, 2010, 201(2): 81-87.
[4]
Yagyu S, Morimoto A, Kakazu N, et al. Late appearance of a Philadelphia chromosome in a patient with therapy-related acute myeloid leukemia and high expression of EVI1[J]. Cancer Genet Cytogenet, 2008, 180(2): 115-120.
Pallisgaard N, Hokland P, Riishoj DC, et al. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia[J]. Blood, 1998, 92(2): 574-588.
[7]
Mitelman F. ISCN 1995: An Intemational System for Human Cytogenetic Nomenclature (1995)[M]. Karger Medical and Scientific Publishers, 1995.
Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases[J]. Biochem Pharmacol, 2012, 83(8): 1041-1048.
[11]
Laurent E, Talpaz M, Kantarjian H, et al.The BCR gene Philadelphia chromosome-positive leukemogenesis[J]. Cancer Res, 2001, 61(6): 2343-2355.
[12]
Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification[J]. Science, 2001, 293(5531): 876-880.
[13]
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues[M]. Lyon, France: IARC, 2008.
[14]
Cuenco GM, Nicifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML[J]. Proc Natl Acad Sci USA, 2000, 97(4):1760-1765.
[15]
Cuenco GM, Ren R. Cooperation of BCR-ABL and AML/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia[J]. Oncogene, 2001, 20(57): 8236-8248.
[16]
Su E, Han X, Jiang G. The transforming growth factor beta 1/SMAD signaling pathway involved in human chronic myeloid leukemia[J]. Tumori, 2010, 96(5): 659-666.
[17]
Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease[J].Nature Med, 2010, 16(2): 198-204.
[18]
Shimada K, Tomita A, Minami Y, et al. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737[J]. Exp Hematol, 2012, 40(9): 724-737.
[19]
Paquette RL, Nicoll J, Chalukya M, et al. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors[J]. Cancer Genet, 2011, 204(7): 392-397.
[20]
Chen G, Yuan SS, Liu W, et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex required ATM and c-Abl[J]. J Biol Chem, 1999, 274(18): 12748-12752.
Konantz M, Andre MC, Ebinger M, et al. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia[J]. Leukemia, 2013, 27(1): 56-65.
